Correlation between exosomal PD-L1 and prognosis in patients with cancer: a systematic review and meta-analysis.

IF 2.5 3区医学 Q2 ONCOLOGY Clinical & Translational Oncology Pub Date : 2025-03-01 Epub Date: 2024-08-23 DOI:10.1007/s12094-024-03620-3

Lijun Huang, Qiurong He, Liping Liu, Jie Huang, Fan Chang

{"title":"Correlation between exosomal PD-L1 and prognosis in patients with cancer: a systematic review and meta-analysis.","authors":"Lijun Huang, Qiurong He, Liping Liu, Jie Huang, Fan Chang","doi":"10.1007/s12094-024-03620-3","DOIUrl":null,"url":null,"abstract":"Background: The predictive role of exosomal programmed cell death ligand l (exoPD-L1) in prognosis has been studied extensively; however, there is still no consensus.Methods: Three databases, including EMBASE, PubMed, and Web of Science, were searched through January 4, 2024. The pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) were used to identify the relationship between circulating exoPD-L1 and prognosis.Results: 15 studies with 1091 patients with cancer were included in this statistical analysis. High exoPD-L1 level was correlated with shorter progression-free survival (PFS) (HR = 2.58, 95% CI: 1.75-3.81) and overall survival (OS) (HR = 1.61, 95% CI: 1.32-1.98). Meanwhile, we found that dynamic upregulation of circulating exoPD-L1 in the early stages of immunotherapy was a favorable factor for prognosis (PFS: HR = 0.34, 95% CI: 0.23-0.51; OS: HR = 0.21, 95% CI: 0.13-0.26).Conclusion: Circulating exoPD-L1 may be a valuable prognostic indicator for patients with cancer and monitoring its changes in the early stages of immunotherapy might be used to predict tumor response and clinical outcome. This conclusion may not apply to superficial tumors.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1288-1298"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03620-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The predictive role of exosomal programmed cell death ligand l (exoPD-L1) in prognosis has been studied extensively; however, there is still no consensus.

Methods: Three databases, including EMBASE, PubMed, and Web of Science, were searched through January 4, 2024. The pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) were used to identify the relationship between circulating exoPD-L1 and prognosis.

Results: 15 studies with 1091 patients with cancer were included in this statistical analysis. High exoPD-L1 level was correlated with shorter progression-free survival (PFS) (HR = 2.58, 95% CI: 1.75-3.81) and overall survival (OS) (HR = 1.61, 95% CI: 1.32-1.98). Meanwhile, we found that dynamic upregulation of circulating exoPD-L1 in the early stages of immunotherapy was a favorable factor for prognosis (PFS: HR = 0.34, 95% CI: 0.23-0.51; OS: HR = 0.21, 95% CI: 0.13-0.26).

Conclusion: Circulating exoPD-L1 may be a valuable prognostic indicator for patients with cancer and monitoring its changes in the early stages of immunotherapy might be used to predict tumor response and clinical outcome. This conclusion may not apply to superficial tumors.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

外泌体 PD-L1 与癌症患者预后的相关性：系统综述和荟萃分析。

背景：外泌体程序性细胞死亡配体 l（exoPD-L1）对预后的预测作用已被广泛研究，但目前仍未达成共识：方法：检索了截至 2024 年 1 月 4 日的三个数据库，包括 EMBASE、PubMed 和 Web of Science。结果：共有15项研究，1091名癌症患者：本次统计分析共纳入了15项研究，1091名癌症患者。高exoPD-L1水平与较短的无进展生存期（PFS）（HR = 2.58，95% CI：1.75-3.81）和总生存期（OS）（HR = 1.61，95% CI：1.32-1.98）相关。同时，我们发现在免疫治疗的早期阶段，循环外显子PD-L1的动态上调是预后的有利因素（PFS：HR = 0.34，95% CI：0.23-0.51；OS：HR = 0.21，95% CI：0.13-0.26）：循环exoPD-L1可能是癌症患者有价值的预后指标，在免疫治疗早期监测其变化可用于预测肿瘤反应和临床预后。这一结论可能不适用于浅表肿瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.